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SeverityAbstract Background: Serum YKL-40 (chitinase-3-like-1) has recently been found to be either the
cause or a biomarker for asthma. This study quantifies serum levels of YKL-40 in asthmatic chil-
dren and evaluates the relationship between YKL-40 and asthma severity.
Methods: We quantified serum YKL-40 levels in two groups of asthmatic children (aged between 2
and 12 years). Group 1 (n: 30) in between the attack (stable group) and group 2 (n: 30) during the
exacerbation (acute attack group). Serum YKL-40 was measured by enzyme-linked immunosorbent
assay (ELIZA) Kits (WKEA MED SUPPLIES CORP). We measured blood eosinophils and peak
expiratory flow rate for children >5 years.
Results: Serum levels of YKL-40 were significantly elevated in the acute asthma group and in the
stable asthma group compared to the control group (673.92 ± 24.23 ng/ml, 552.73 ± 57.34 ng/ml,
136.17 ± 53.14) respectively, P< 0.001. YKL-40 levels were correlated positively with blood eosi-
nophils in the stable group (q= 0.67, P< 0.001) and in the acute attack group (q= 0.76,
P< 0.001). It is inversely correlated with PEFR in the stable asthma group (q= 0.83,
P< 0.001) and in the acute asthma group (q= 0.88, P< 0.001).
Conclusions: Serum YKL-40 protein was found in increased quantities in patients with asthma in
whom the protein level correlated positively with the severity of disease so our data concluded that
YKL-40 could be a valuable biomarker for asthma diagnosis and prognosis.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Pediatric
Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Asthma is a chronic inflammatory disease characterized by
recurrent attacks of breathlessness and wheezing, which vary
in severity and frequency from person to person.1 Asthma isbest thought of as an immunologically mediated disease, in
which an abnormal immune response to various inhaled
environmental agents and irritants provoke a cascade of events
that lead to mucus hypersecretion, airway constriction and
hyper-responsiveness and ultimately symptoms.2
YKL-40 (chitinase-3-like-1 [CHI3L1]), (human cartilage
glycoprotein-39), is a member of the mammalian chitinase-
like protein class. It is a 40 kDA heparin binding glycoprotein.
The name YKL-40 is derived from the protein’s molecular
weight and three N-terminus amino acids (tyrosine, lysine
YKL-40 in asthmatic children 27and leucine).3 YKL-40 binds chitin which is an abundant, nat-
urally occurring polysaccharide composed of N-
acetylglucosamine repeats functioning as a major structural
polymer in many lower life forms including cell walls of bacte-
ria and fungi but YKL-40 is deficient in chitinase activity. It is
produced at sites of inflammation in many cells and is secreted
from vascular smooth muscle cells and macrophages.4
YKL-40 is synthesized in neutrophil precursors at the mye-
locyte–metamyelocyte stage; it is stored in specific granules of
neutrophils and released from fully activated cells as well as
from macrophages, neutrophils, chondrocytes, vascular
smooth muscle and cancer cells.5 It is suggested that YKL-
40 has a role in inflammation and tissue remodeling in human
diseases, such as joint injury, liver fibrosis, type 2 diabetes.4,3,6
It is established that YKL-40 was increased in the lung and cir-
culation of patients with severe asthma. Thereby, they rea-
soned that YKL-40 could either be a cause or marker for
asthma.7,8
Patients
This case control study was conducted on 90 children at pedi-
atric allergy clinic and emergency department of Benha
University Hospital over a period of 1 year from December
2012 to December 2013. Sixty asthmatic children randomly
selected took part in the present study. Their ages ranged from
2 to 12 years and were 41 males and 19 females. Thirty appar-
ently normal children of comparable age, sex and socioeco-
nomic status were taken as a control group. Patients with
concomitant diseases such as cancer, arthritis, hepatic fibrosis
and diabetes were excluded from the study.
Asthmatic subjects were divided into two subgroups: stable
group (n: 30) was recruited during their scheduled clinic visit.
Their symptoms and pulmonary functions were stable and
divided into intermittent, mild persistent, moderate persistent
and severe persistent. Acute attack group (n: 30) was divided
into mild attack, moderate attack and severe attack according
to GINA (Global initiative for asthma) criteria.9
Methods
The study protocol received approval of the research ethics
committee of the pediatric department at Benha University.
All candidates were subjected to: detailed medical history tak-
ing, Clinical examination, peak expiratory flow rate (PEFR)
by peak flow meter. Chest X-ray to exclude chest diseases
other than asthma and Laboratory investigation included:
complete blood count (CBC) with eosinophilic count and assay
of serum YKL-40 level.
Assay of serum YKL-40 level: serum samples for YKL-40
(ng/ml) were centrifuged for 10 min at 3000 rpm and
stored at 20 C in Eppendrof vials. Human YKL-40
enzyme-linked immunosorbent assay (ELISA) kit (WKEA
MED SUPPLIES CORP, Changchun 130012 China) was used
for the serum YKL-40 level measurements. Assay range:
5–200 ng/ml.
Statistical analysis
The collected data were summarized as mean ± SD and range
for quantitative data and proportions for qualitative data.Differences between the study groups regarding the studied
parameters were tested using the Chi-squared (v2) test to com-
pare proportions, the Mann–Whitney test to compare two
groups and the Kruskal–Wallis test to compare more than
two groups. Spearman correlation coefficient (rho; q) was used
to assess the correlation between serum levels of YKL-40 and
some parameters. After the calculation of each of the test
statistics, the corresponding distribution tables were consulted
to get the ‘‘P” (probability value). Statistical significance
was accepted at P value <0.05. The cut off value of serum
YKL-40 for screening of asthma and the corresponding sensi-
tivity, specificity were calculated. All statistical analyses were
carried out in STATA/SE version 11.0 for Windows.
Results
Demographic and laboratory data for the study subjects are
demonstrated in Tables 1 and 2. The mean serum YKL-40
level of the control group was found to be (136.17 ± 53.14)
ng/ml. Mean serum YKL-40 level of the patients in stable
asthma group was (552.73 ± 57.34) ng/ml while the mean
serum of YKL-40 in patients of the acute asthma group was
(673.92 ± 24.23) ng/ml respectively. There was a significant
difference between serum YKL-40 levels of the stable asthma
group and the acute asthma group P< 0.001. Fig. 1 shows
differences in the serum level of YKL-40 between the study
groups.
Correlations between serum YKL-40 and other variables
are demonstrated in Table 3. There was a significant positive
correlation between serum YKL-40 and blood eosinophils in
both asthmatic groups (q= 0.67, P< 0.001) & (q= 0.76,
P< 0.001) respectively. Also, there was a significant negative
correlation between PEFR and serum YKL-40 in both asth-
matic groups (q= 0.83, P< 0.001) & (q= 0.88,
P< 0.001) respectively. Fig. 2 shows Sensitivity and specificity
curves and cut-off level of YKL-40 for diagnosis and screening
of asthma. The best cut off value of YKL-40 for diagnosis and
screening of asthma was 216.8 ng/ml.
Discussion
Chitinases are among one of the recently described proteins
suggested to play a pivotal role in T-helper 2 (Th2)-mediated
inflammation and allergic diseases such as asthma.10 Circulat-
ing YKL-40 levels regulated by Polymorphisms in the CHI3L1
(chitinase 3-like 1-proteins) gene. Regulatory SNPs in CHI3L1
were associated with asthma, atopy, and immune-mediated
diseases.11 In asthma, YKL-40 are secreted from macrophages
and airway epithelial cells with IL-13 related mechanism. Th-2
associated inflammatory response due to allergen exposure,
which results in airway hyperresponsiveness and smooth mus-
cle contraction, plays a role in tissue remodeling.12
The sex distribution in our study among asthmatic patients
revealed male predominance (68.33%) than females (31.67%)
with a male to female ratio of 2.1:1 but the difference was sta-
tistically insignificant. This finding is supported by studies
done by Khaldi et al.13 and Awad14 who reported that was
no sex difference in pediatric asthma. Anupama et al.15 showed
a significant male predominance. Concerning residence distri-
bution, in the present study, 70% of asthmatic children were
from urban areas while, 30% were from rural areas with a
Table 1 Demographic data of study groups.
Variable Controls N= 30 Cases N= 60 Test P-value
Age (years) Mean ± SD; (range) 5.57 ± 2.50; (2–11) 5.87 ± 3.0; (2–12) Z* = 0.16 0.87
Sex Male (%) 17 (56.67) 41 (68.33) v2 = 1.19 0.28
Female (%) 13 (43.33) 19 (31.67)
Residence Urban (%) 13 (43.33) 42 (70.00) v2 = 5.98 0.01
Rural (%) 17 (56.67) 18 (30.00) (S)
Family size 64 (%) 12 (40.00) 22 (36.67) v2 = 0.09 0.76
>4 (%) 18 (60.00) 38 (63.33)
Parents education High (%) 17 (56.67) 19 (31.67) v2 = 5.21 0.02
Low (%) 13 (43.33) 41 (68.33) (S)
Family history of atopic diseases Positive (%) 3 (10.00) 44 (73.33) v2 = 32.15 <0.001
Negative (%) 27 (90.00) 16 (26.67) (HS)
Age at onset of asthma (years) Mean ± SD; (range) 2.13 ± 1.23; (1–6)
Z* – obtained using Mann–Whitney test.
Table 2 Clinical and laboratory data of study groups.
Variable Mean ± SD; (range) Z1* P1 Z2* P2 Z3* P3
Controls N= 30 Asthma group 1
(stable) N= 30
Asthma group 2
(acute) N= 30
PEFR% 87.18 ± 3.71; (80–
95) N= 17
72.33 ± 11.73; (58–
89) N= 15
66.87 ± 11.39; (50–
82) N= 15
3.53 <0.001
(HS)
4.70 <0.001
(HS)
1.25 0.21
Hb (gm/dl) 12.25 ± 0.84; (9.7–
13.5)
10.36 ± 1.26; (8.2–
12.3)
10.39 ± 1.77; (7.8–
13.5)
5.28 <0.001
(HS)
4.03 <0.001
(HS)
0.13 0.90
Total
leukocytic
count
6.54 ± 1.75; (4–10) 8.87 ± 3.68; (4–20.3) 9.84 ± 3.05; (4.9–16) 2.72 0.007 (S) 4.30 <0.001
(HS)
1.38 0.17
Eosinophils 204.37 ± 61.88;
(90–300)
535.2 ± 85.44; (360–
690)
616.67 ± 77.92; (500–
790)
6.66 <0.001
(HS)
6.66 <0.001
(HS)
3.58 <0.001
(HS)
Ykl 40 (ng/ml) 136.17 ± 53.14;
(36–198.5)
552.73 ± 57.34; (440–
680.5)
673.92 ± 24.23;
(607.5–714)
6.66 <0.001
(HS)
6.66 <0.001
(HS)
6.10 <0.001
(HS)
Z1 and P1 for comparing controls with asthma group 1; Z2 and P2 for comparing controls with asthma group 2; Z3 and P3 for comparing
Asthma group 1 and asthma group 2.
Z* – obtained using Mann–Whitney test.
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Figure 1 Differences in the serum levels of YKL-40 between the
study groups.
Table 3 Correlation between serum YKL-40, age, age at
onset of asthma, eosinophils and PEFR% among patients of
group 1 (stable asthma group) and group 2 (acute asthma
group).
Variable Serum YKL-40 (ng/ml)
Asthma group 1 (stable
asthma)
Asthma group 2 (acute
asthma)
No q P-value No q P-value
Age (years) 30 0.32 0.09 30 0.15 0.43
Age of onset
(years)
30 0.55 0.002 (S) 30 0.15 0.42
Eosinophils 30 0.67 <0.001
(HS)
30 0.76 <0.001
(HS)
HB (gm/dl) 30 0.14 0.45 30 0.02 0.91
PEFR% 15 0.83 <0.001
(HS)
15 0.88 <0.001
(HS)
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             Sensitivity and specificity curves
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Figure 2 Cut-off level of YKL-40 for diagnosis and screening of asthma.
YKL-40 in asthmatic children 29statistically significant difference (P= 0.01). Colilla et al.16
found that a higher percentage of asthmatic students living
in urban areas compared to asthmatic students living in rural
areas and they explained that by high air pollution in urban
areas. In contrast to this, Morrison et al.17 reported that
asthma prevalence was as high in rural as in urban areas.
From our results, the prevalence of asthmatic children
whose family size > 4 (63.33%) was more than children whose
family size 6 4 (36.67%) but no significant differences were
seen among groups. Nafstad et al.18 detected higher asthma
prevalence in larger families. On the other hand Westergaard
and Melby19 have found an inverse relation between asthma
prevalence and family size, where children in large families
showed a lower prevalence of asthma but there is no biological
explanation for this observation.
In this study, the mean age at onset of the disease among
asthmatic children was (2.13 ± 1.23) years. Masuda and Fuji-
sawa20 found that the mean age of onset of asthma was
2.8 years. However, Abd el-Fattah et al.21 reported that about
50% of asthmatics experienced their first symptoms before
2 years of age. Hossny et al.22 found the mean age of onset
of studied groups was one year. This highlights the role of viral
infections as inducers of wheezing in infancy.
As regards the laboratory data of the studied children, we
found that asthmatic patients had a highly significant decrease
in their hemoglobin level than the control group. This agreed
with Ramakrishnan and Borade23 who found that anemic chil-
dren are 5.75 times more susceptible to develop childhood
asthma compared to the non-anemic children. Fida and Kam-
far24 detected low values for hematocrit (41.0%), mean corpus-
cular volume (41.9%), hemoglobin (17.9%), platelets (0.9%),
iron (5.1%) and ferritin (12.0%) in asthmatic patients. They
concluded that iron deficiency anemia could be considered as
a risk factor in asthmatic patients.
As regards TLC, there was significant difference between
stable asthma and controls (P= 0.007) and highly significant
difference between acute the asthma group and controls(P< 0.001). Mann and Chung25 reported that the circulating
neutrophil in severe asthma shows evidence of activation, as
measured by the increased expression of the adhesion mole-
cules, CD11b and CD35 and are not inhibited by oral corticos-
teroids. So, they may be important in the pathogenesis of
severe asthma Kikuchi et al.26 suggested that neutrophils that
have migrated to IL-8 may subsequently cause eosinophils to
accumulate in the asthmatic airways.
Our results showed a highly significant increase in eosino-
philic count among asthmatic children in the stable group
and acute asthma group compared to the control group
(P< 0.001). Our results were in agreement with those of
Simpson et al.27 who found that at most about one-half of
asthma cases appear to be due to allergic mechanisms. Bous-
quet and Vignola28 have shown that the number of eosinophils
in peripheral blood and in bronchial lavage from subjects with
asthma is associated with more severe disease. In contrast,
Jayaram et al.29 had a study which showed that patients may
have severe and persistent asthma in the absence of eosinophi-
lic inflammation, and they may experience an exacerbation of
asthma without an increase in eosinophilic inflammation.
In our study, we found that asthmatic children had a highly
significant decrease in PEFR% level when compared to the
controls (P< 0.001). In agreement, Stout et al.30 found a
decrease in the FEV1/forced vital capacity ratio as asthma
severity increased. O’Byrne et al.31 showed that severe asthma
exacerbation may result in an accelerated loss of pulmonary
function. Patients who frequently experienced asthma exacer-
bation showed a greater annual decline in FEV1 than those
with infrequent exacerbations.
In this study, we found that the serum YKL-40 level was
higher in the acute asthma group than patients in stable
asthma group and the control group. Kuepper et al.8 measured
YKL-40 levels in serum before and 24 h after a segmental aller-
gen challenge in 13 patients with allergic asthma, YKL-40 con-
centrations were significantly elevated in the serum before
challenge (P= 0.01) and even more elevated (P= 0.003)
30 I.A. Mohammed et al.24 h after allergen. Chupp et al.7 quantified serum YKL-40
levels in three cohorts of patients with asthma and showed that
circulating levels of YKL-40 were increased in patients with
asthma, as compared with healthy persons (median, 97.7 ng
per milliliter). Duru et al.32 found a significant difference
between serum YKL-40 levels of well controlled asthma
patients and the acute exacerbation group (P< 0.0001).
Konradsen et al.33 reported that serum YKL-40 levels were
significantly higher in children with therapy-resistant asthma
than in healthy children (P= 0.03). Also, Specjalski et al.34
revealed that in asthmatics, the level was significantly higher
in the subgroup with poor control of symptoms and exacerba-
tions compared to stable asthmatics (P< 0.001).
In our study, serum YKL-40 showed a highly significant
positive correlation with eosinophilic count in the stale asthma
group and in acute asthma. This agreed with Tang et al.35 and
Lee et al.36 who reported that there were positive correlations
between seum levels of YKL-40 and peripheral blood eosino-
phils. In our study, serum YKL-40 levels showed a highly sig-
nificant negative correlation with PEFR in stable asthma cases
and in acute asthma cases. Otsuka et al.37 found that sputum
YKL-40 levels were negatively correlated with pre- and post-
bronchodilator % FEV 1 (r= 0.47 and 0.42, respectively;
P< 0.01) and forced mid-expiratory flow (r= 0.48 and
0.46, respectively, P< 0.01). Also, Saba et al.38 showed a
negative correlation with different spirometric indices in such
a way that it was significant with FEV1/FVC and FEF
25–75%.
Conclusion
In conclusion, Circulating YKL-40 protein was found in
increased quantities in patients with asthma in whom the pro-
tein level correlated positively with the severity of disease so
our data concluded that YKL-40 could be a valuable biomar-
ker for asthma diagnosis and prognosis.
Recommendations
Although our data suggest that YKL-40 either participates in
the pathogenesis of asthma or is a biomarker of severity,
prospective studies will be required to evaluate the potential
role of serum YKL-40 levels in the management of asthma
and asthma research. Further studies to investigate genetic
polymorphism of YKL-40 in the Egyptian population are sug-
gested to be performed.
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